Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: A randomized controlled trial

Diabetic Medicine

Volumn 17, Issue 11, 2000, Pages 762-770

  Home, P D ^a,b,c   Lindholm, A ^a,b   Riis, A ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c Department of Medicine ^*  (United Kingdom)

Author keywords

Hypoglycaemia; Insulin analogue; Insulin aspart; Insulin therapy; Quality of life; Rapid acting insulin; Type 1 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; ISOPHANE INSULIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0034537104     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2000.00380.x     Document Type: Article

References (30)

1. The effect of intensive treatment of diabetes on the development and the progression of long-term complications in insulin-dependent diabetes mellitus
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
3. Insulin therapy
4. Intensive insulin therapy for treatment of Type 1 diabetes
5. Time-action profile of the insulin analogue B28Asp
6. Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients
7. Improved postprandial glycaemic control with insulin aspart - A randomized double-blind cross-over trial in type 1 diabetes mellitus
8. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic β-cell function
9. Monomeric insulins obtained by protein engineering and their medical implications
10. Insulin: The structure in the crystal and its reflection in chemistry and biology
11. Comparison of subcutaneous soluble human insulin and insulin analogues (Asp(B9), Glu(B27); Asp(B10); Asp(B28)) on meal related plasma glucose excursions in Type 1 diabetic subjects
12. Measures of psychological well-being and treatment satisfaction developed form responses of people with tablet-treated diabetes
13. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life threatening conditions. Adopted by CPMP, issued as CPMP/ICH/375/95
14. A useful testing strategy for phase III trials: Combined test of superiority and equivalence
15. Chapter 6. Log-linear models
16. Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen: A questionnaire study
17. Interval between insulin injection and meal in relation to blood glucose control
18. Improved mealtime treatment of diabetes mellitus using an insulin analogue
19. Reduction of postprandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment
20. Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: Importance of appropriate replacement of basal insulin and time-interval injection-meal
21. Long-term intensive treatment of type 1 diabetes with the short- acting insulin analog lispro in variable combination with NPH insulin at mealtime
22. The absence of a glycaemic threshold for development of long-term complications: The perspective of the DCCT
23. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers
24. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up
25. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro
26. Effects of the short-acting insulin analog [Lys (B28),Pro (B29)] on postprandial blood glucose control in IDDM
27. Optimization of evening insulin dose in patients using the short-acting insulin analogue lispro
28. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients